ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS. AGOURA HILLS, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...